Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions.

Ferrao R, Lupardus PJ.

Front Endocrinol (Lausanne). 2017 Apr 18;8:71. doi: 10.3389/fendo.2017.00071. eCollection 2017. Review.

2.

Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).

Min X, Ungureanu D, Maxwell S, Hammarén H, Thibault S, Hillert EK, Ayres M, Greenfield B, Eksterowicz J, Gabel C, Walker N, Silvennoinen O, Wang Z.

J Biol Chem. 2015 Nov 6;290(45):27261-70. doi: 10.1074/jbc.M115.672048. Epub 2015 Sep 10.

3.

Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome.

Kreins AY, Ciancanelli MJ, Okada S, Kong XF, Ramírez-Alejo N, Kilic SS, El Baghdadi J, Nonoyama S, Mahdaviani SA, Ailal F, Bousfiha A, Mansouri D, Nievas E, Ma CS, Rao G, Bernasconi A, Sun Kuehn H, Niemela J, Stoddard J, Deveau P, Cobat A, El Azbaoui S, Sabri A, Lim CK, Sundin M, Avery DT, Halwani R, Grant AV, Boisson B, Bogunovic D, Itan Y, Moncada-Velez M, Martinez-Barricarte R, Migaud M, Deswarte C, Alsina L, Kotlarz D, Klein C, Muller-Fleckenstein I, Fleckenstein B, Cormier-Daire V, Rose-John S, Picard C, Hammarstrom L, Puel A, Al-Muhsen S, Abel L, Chaussabel D, Rosenzweig SD, Minegishi Y, Tangye SG, Bustamante J, Casanova JL, Boisson-Dupuis S.

J Exp Med. 2015 Sep 21;212(10):1641-62. doi: 10.1084/jem.20140280. Epub 2015 Aug 24.

4.

A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.

Sohn SJ, Barrett K, Van Abbema A, Chang C, Kohli PB, Kanda H, Smith J, Lai Y, Zhou A, Zhang B, Yang W, Williams K, Macleod C, Hurley CA, Kulagowski JJ, Lewin-Koh N, Dengler HS, Johnson AR, Ghilardi N, Zak M, Liang J, Blair WS, Magnuson S, Wu LC.

J Immunol. 2013 Sep 1;191(5):2205-16. doi: 10.4049/jimmunol.1202859. Epub 2013 Jul 26.

5.

Ligand-independent interaction of the type I interferon receptor complex is necessary to observe its biological activity.

Krause CD, Digioia G, Izotova LS, Xie J, Kim Y, Schwartz BJ, Mirochnitchenko OV, Pestka S.

Cytokine. 2013 Oct;64(1):286-97. doi: 10.1016/j.cyto.2013.06.309. Epub 2013 Jul 3.

6.

TYK2 kinase activity is required for functional type I interferon responses in vivo.

Prchal-Murphy M, Semper C, Lassnig C, Wallner B, Gausterer C, Teppner-Klymiuk I, Kobolak J, Müller S, Kolbe T, Karaghiosoff M, Dinnyés A, Rülicke T, Leitner NR, Strobl B, Müller M.

PLoS One. 2012;7(6):e39141. doi: 10.1371/journal.pone.0039141. Epub 2012 Jun 18.

7.

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, Marque F, Régnier CH, De Pover A, Ryckelynck H, Bhagwat N, Koppikar P, Goel A, Wyder L, Tavares G, Baffert F, Pissot-Soldermann C, Manley PW, Gaul C, Voshol H, Levine RL, Sellers WR, Hofmann F, Radimerski T.

Cancer Discov. 2012 Jun;2(6):512-523. doi: 10.1158/2159-8290.CD-11-0324. Epub 2012 May 3.

8.

Janus kinase 3: the controller and the controlled.

Wu W, Sun XH.

Acta Biochim Biophys Sin (Shanghai). 2012 Mar;44(3):187-96. doi: 10.1093/abbs/gmr105. Epub 2011 Nov 29. Review.

9.

Simian immunodeficiency virus infection in the brain and lung leads to differential type I IFN signaling during acute infection.

Alammar L, Gama L, Clements JE.

J Immunol. 2011 Apr 1;186(7):4008-18. doi: 10.4049/jimmunol.1003757. Epub 2011 Mar 2.

10.

A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis.

Spach KM, Noubade R, McElvany B, Hickey WF, Blankenhorn EP, Teuscher C.

J Immunol. 2009 Jun 15;182(12):7776-83. doi: 10.4049/jimmunol.0900142.

11.

Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling.

Robertson SA, Koleva RI, Argetsinger LS, Carter-Su C, Marto JA, Feener EP, Myers MG Jr.

Mol Cell Biol. 2009 Jun;29(12):3367-78. doi: 10.1128/MCB.00278-09. Epub 2009 Apr 13.

12.

Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling.

Ishida-Takahashi R, Rosario F, Gong Y, Kopp K, Stancheva Z, Chen X, Feener EP, Myers MG Jr.

Mol Cell Biol. 2006 Jun;26(11):4063-73. Erratum in: Mol Cell Biol. 2006 Aug;26(16):6309.

13.

Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.

Hofmann SR, Lam AQ, Frank S, Zhou YJ, Ramos HL, Kanno Y, Agnello D, Youle RJ, O'Shea JJ.

Mol Cell Biol. 2004 Jun;24(11):5039-49.

14.

Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling.

Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers MG Jr.

Mol Cell Biol. 2004 Jun;24(11):4968-78.

15.

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Saharinen P, Vihinen M, Silvennoinen O.

Mol Biol Cell. 2003 Apr;14(4):1448-59.

16.

The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.

Ragimbeau J, Dondi E, Alcover A, Eid P, Uzé G, Pellegrini S.

EMBO J. 2003 Feb 3;22(3):537-47.

17.

Jaks, STATs, Cytokines, and Sepsis.

Scott MJ, Godshall CJ, Cheadle WG.

Clin Diagn Lab Immunol. 2002 Nov;9(6):1153-9. Review. No abstract available.

18.

A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling.

Yeh TC, Dondi E, Uze G, Pellegrini S.

Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8991-6.

20.

Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.

Saharinen P, Takaluoma K, Silvennoinen O.

Mol Cell Biol. 2000 May;20(10):3387-95.

Supplemental Content

Support Center